Lobe Sciences, Ltd. is a biopharmaceutical company engaged in both commercial and research activities. In 2023, the company underwent significant changes, including new ownership, a new Board of Directors, and a new management team.
Dr. Fred D. Sancilio was appointed as the Chairman and Chief Executive Officer, bringing over 40 years of experience in developing new medicines that are now sold globally. Not only is he leading the Company, but is currently a majority shareholder. Lobe is one of the rare public companies being led by a successful entrepreneur “with skin in the game”. As the majority shareholder, he is focused on success of the Company, its patients and his fellow stakeholders!
The company has developed a new chemical entity called L-130, or Conjugated Psilocin. Stabilizing psilocin has been a challenge for scientists for over a century. Since a stable form of this promising drug candidate couldn’t be found, researchers used a “prodrug” called psilocybin, which is naturally occurring and has hallucinogenic properties. After years of research, our scientists discovered and patented a stabilized form of psilocin and have entered animal and human clinical studies.
Our findings could revolutionize the industry. Our patented psilocin is fully bioavailable and is completely absorbed in less than an hour. Compared to psilocybin, it is twice as bioavailable and enters circulation twice as fast. This means that a drug product made with our unique psilocin will be highly reproducible, independent of metabolism, and can be used in much lower doses, thereby eliminating the potential for hallucinations.
The first therapeutic application of Conjugated Psilocin will be to help the thousands of people suffering from a terrible disease called chronic cluster headache. You can learn about this disease elsewhere in the website. We have already completed first-in-man clinical trials, multiple animal studies and laboratory studies that all indicate we have a viable and valuable new drug candidate. Once we’ve completed additional clinical work with this indication, we plan to evaluate Conjugated Psilocin for other indication and in particular its application to treat addiction. We believe that Conjugated Psilocin may become a solution for the millions of people suffering from substance use disorder (SUD) which is the unspoken epidemic larger than any other disease in the world! Imagine if Lobe Sciences were able to impact just 1% of addiction and how that would change the life of so many victims of this world!
We have also developed technology to assist thousands of patients with sickle cell disease. Our Altemia program aims to bring new hope to children suffering from this severe genetic disorder. Currently, few patients with sickle cell disease can tolerate the available treatments. However, Lobe Sciences, through its subsidiary Altemia, Inc., will soon introduce a medical food specifically designed to correct a metabolic error found in this rare genetic disorder. Our great-tasting medical food, taken daily, will restore the natural balance of fatty acids altered by sickle cell disease. Clinical studies have shown improvements in overall wellbeing, fewer doctor’s visits, and reduced hospitalizations.
Our team at Lobe Sciences is enthusiastic about the future, and we hope you will continue to visit our website to learn more about our company and how you can be a part of it too!